The prognostic value of lymph node yield in the earliest stage of colorectal cancer: a multicenter cohort study

Backes, Yara; Elias, Sjoerd G.; Bhoelan, Bibie S.; Groen, John N.; van Bergeijk, Jeroen; Seerden, Tom C. J.; Pullens, Hendrikus J. M.; Spanier, Bernhard W. M.; Geesing, Joost M. J.; Kessels, Koen; Kerkhof, Marjon; Siersema, Peter D.; de Vos tot Nederveen Cappel, Wouter H.; van Lelyveld, Niels; Wolfhagen, Frank H. J.; ter Borg, Frank; Offerhaus, G. Johan A.; Lacle, Miangela M.; Moons, Leon M. G.

doi:10.1186/s12916-017-0892-7

Table 1 Baseline characteristics for patients with a LN yield < 10 vs. ≥ 10

From: The prognostic value of lymph node yield in the earliest stage of colorectal cancer: a multicenter cohort study

	Baseline characteristics original cohort		Baseline characteristics LN yield < 10 vs. ≥ 10
			Unadjusted data^a			IPW adjusted data for the confounders considered for the primary analysis^a,c			IPW adjusted data for the confounders considered for the secondary supporting analysis^a,d
	N = 1017^a	Missing (%)^b	LN yield < 10 N = 612	LN yield ≥ 10 N = 405	P value	LN yield < 10 N = 612	LN yield ≥ 10 N = 405	P value	LN yield < 10 N = 612	LN yield ≥ 10 N = 405	P value
Age in years	69.1	0.5	68.6	69.7	0.07	69.1	69.0	0.47	69.1	69.1	0.74
Male sex	54.6	0	55.7	52.8	0.40	54.6	54.0	0.30	54.5	53.7	0.35
BMI in kg/m²	26.9	27.9	26.9	27.0	0.70	26.8	27.0	0.54	26.7	27.1	0.46
ASA score		0.4
- ASA I - ASA II - ASA III–IV	29.7 49.5 20.8	0.4	31.6 47.5 20.9	26.9 52.3 20.7	0.13 0.15 0.99	30.3 47.8 21.8	29.0 52.0 18.9	0.67 0.20 0.24	30.1 48.0 21.9	29.1 51.8 19.0	0.79 0.25 0.25
Tumor location		0
- Right colon - Left colon - Rectum	24.1 58.8 17.1	0	15.2 68.6 16.2	37.5 44.0 18.5	<0.001 <0.001 0.38	24.2 58.7 17.0	24.1 58.8 17.1	0.62 0.89 0.67	23.9 59.0 17.1	23.9 58.9 17.2	0.84 0.83 0.85
Tumor morphology		5.0
- Pedunculated - Non-pedunculated	33.4 66.6	5.0	39.3 60.7	24.1 75.9	<0.001 <0.001	33.3 66.7	33.7 66.3	0.39 0.39	33.4 66.6	33.7 66.3	0.68 0.68
Tumor size in cm	2.7	9.4	2.6	2.9	0.003	2.7	2.7	0.82	2.7	2.7	0.82
Lymph node metastasis	8.3	0	6.0	11.6	0.002	8.6	8.5	0.91	8.3	8.4	0.75
Adjuvant chemotherapy	4.4	0	3.6	5.7	0.15	4.6	4.5	0.92	4.4	4.6	0.82
Lymphovascular invasion		53.8
- Absent - Present	79.2 20.8	53.8	70.1 29.9	79.8 20.2	0.04 0.04	69.7 30.3	78.9 21.1	0.03 0.03	73.3 26.7	73.2 26.8	0.70 0.70
Differentiation grade		18.5
- Well - Moderate - Poor	14.0 80.6 5.4	18.5	14.9 79.4 5.7	12.7 82.3 5.0	0.44 0.31 0.63	15.1 79.6 5.4	12.9 82.0 5.1	0.47 0.41 0.59	14.1 80.6 5.3	14.2 80.7 5.1	0.71 0.73 0.62
Invasion depth		50.3
- Haggitt I/II/III or SM1 - Haggitt IV or SM2/3	44.9 55.1	50.3	47.3 52.7	41.4 58.6	0.21 0.21	43.7 56.3	45.8 54.2	0.67 0.67	44.6 55.4	44.3 55.7	0.83 0.83

ASA American Society of Anesthesiologists, BMI body mass index, cm centimeter, IPW inverse probability weighting, kg kilogram, LN lymph node, m meter
^aValues are means for continuous variables and percentages for categorical variables
^bPercentage of patients with missing data in the original cohort
^cInverse probability weighting was based on age, sex, tumor location, tumor size, tumor morphology and the presence of lymph node metastasis (primary analysis)
^dInverse probability weighting was based on age, sex, tumor location, tumor size, tumor morphology, invasion depth, presence of lymphovascular invasion, differentiation grade, and presence of lymph node metastasis (secondary supporting analysis)

Back to article page

ISSN: 1741-7015

Contact us

Submission enquiries: bmcmedicineeditorial@biomedcentral.com
General enquiries: info@biomedcentral.com

BMC Medicine

Contact us